A Study to Evaluate the Effects of Single and Multiple Doses of Hemay005 Tablets in Health Caucasian Adult Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

July 17, 2023

Primary Completion Date

August 8, 2023

Study Completion Date

August 20, 2023

Conditions
Healthy
Interventions
DRUG

Hemay005 60 mg

"The eligible healthy adult participants will enter Single-dose Administration Period, receiving a single administration of Hemay005 tablets orally at a dose of 60 mg on Day 1 morning under fasted condition.~On Day 3, those participants will receive Hemay005 tablets at dose of 60 mg for 7 consecutive days, which will be administrated twice daily (BID) during Day 3 to Day 8 and only in the morning on Day 9."

Trial Locations (1)

2031

Scientia Clinical Research Ltd, Randwick

All Listed Sponsors
collaborator

Hemay Pharmaceutical PTY. LTD.

INDUSTRY

lead

Ganzhou Hemay Pharmaceutical Co., Ltd

INDUSTRY